The prostate condition, benign prostatic hyperplasia, is very prevalent in men. There are some signs of the disease in 8 per cent of 31 to 40 year olds, in over 40 per cent of 51 to 60 year olds, and 80 per cent of those over 80 years. The condition causes the prostate to swell, enlarge and stiffen, squeezing and narrowing the exit from the bladder, and making urination slow and painful. If the condition is thought serious enough, corrective surgery is undertaken.

The prostate is a gland in males which surrounds the neck of the bladder and the urethra. It is formed as three lobes containing glandular matter with ducts which empty fluid into the urethra. The secretions from the ducts are a fluid which is added to coagulated seminal fluid, making it more liquid and giving semen its characteristic smell. In a normal prostate during ejaculation there is a copious outflow through the prostatic ducts. At other times there is an insensible passage of some of the liquid though the ducts.

The ducts are havards, and if there is even a slight increase in speed of liquid in the ducts, then the duct actively modifies the liquid and its anti-microbial property is lost. Normal microbes can then enter the ducts from the urethra and the immune reaction to the microbes blocks the duct. The prostatic fluid continues to be output but cannot pass into the urethra because of the blockage. The pressure of the liquid in the prostate gland causes its enlargement and the consequent prostate condition.

For the first time in history, this is the detail of the aetiology of this common prostate condition.

There is known to be an association of benign prostatic hyperplasia with essential hypertension. In fact, they are both miliaria class conditions.

Treatment of the prostate condition is aimed at keeping the ducts open so that the condition does not occur. ActivSignal^TM Sodium, which is highly effective for essential hypertension, will also treat and prevent prostatic disease. The first commercial ActivSignal product is now under development. A benefit of concurrent treatment of both these miliaria class diseases in men is likely to be restoration of sexual function and fertility, and a reduction in lower urinary tract symptoms.